Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

Palmerini T., 2012, Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis., Lancet., 379, 1393, 10.1016/S0140-6736(12)60324-9

Stefanini GG., 2013, Drug-eluting coronary-artery stents., N Engl J Med., 368, 254, 10.1056/NEJMra1210816

Onuma Y., 2011, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation., 123, 779, 10.1161/CIRCULATIONAHA.110.971606

Serruys PW., 2011, Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes., J Am Coll Cardiol., 58, 1578, 10.1016/j.jacc.2011.05.050

Simsek C., 2013, Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)., EuroIntervention., 10, 236, 10.4244/EIJV10I2A38

Muramatsu T., 2014, 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials., JACC Cardiovasc Interv., 7, 482, 10.1016/j.jcin.2014.01.155

Gori T., 2014, Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes., EuroIntervention., 9, 1036, 10.4244/EIJV9I9A176

Kocka V., 2014, Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’., Eur Heart J., 35, 787, 10.1093/eurheartj/eht545

Diletti R., 2014, Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study., Eur Heart J., 35, 777, 10.1093/eurheartj/eht546

Diletti R., 2012, ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design., Am Heart J., 164, 654, 10.1016/j.ahj.2012.08.010

Cutlip DE., 2007, Clinical end points in coronary stent trials: a case for standardized definitions., Circulation., 115, 2344, 10.1161/CIRCULATIONAHA.106.685313

Taylor J., 2012, Third universal definition of myocardial infarction., Eur Heart J., 33, 2506, 10.1093/eurheartj/ehs105

Palmerini T., 2013, Stent thrombosis with drug-eluting stents: is the paradigm shifting?, J Am Coll Cardiol., 62, 1915, 10.1016/j.jacc.2013.08.725

Nakatani S., 2014 Feb 27., Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial., EuroIntervention., Epub AOP

Serruys PW., 2010, Comparison of zotarolimus-eluting and everolimus-eluting coronary stents., N Engl J Med., 363, 136, 10.1056/NEJMoa1004130

von Birgelen C., 2012, A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial., J Am Coll Cardiol., 59, 1350, 10.1016/j.jacc.2012.01.008

Stone GW., 2011, Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus., Circulation., 124, 893, 10.1161/CIRCULATIONAHA.111.031070

Kedhi E., 2014, Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials., J Am Coll Cardiol., 63, 2111, 10.1016/j.jacc.2014.01.064

Holmes DR Jr., 2010, Stent thrombosis., J Am Coll Cardiol., 56, 1357, 10.1016/j.jacc.2010.07.016

Attizzani GF., 2014, Mechanisms, pathophysiology, and clinical aspects of incomplete stent apposition., J Am Coll Cardiol., 63, 1355, 10.1016/j.jacc.2014.01.019

Lotan C., 2009, Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry., JACC Cardiovasc Interv., 2, 1227, 10.1016/j.jcin.2009.10.001

Krucoff MW., 2011, A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)., JACC Cardiovasc Interv., 4, 1298, 10.1016/j.jcin.2011.08.010

Kolandaivelu K., 2011, Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings., Circulation., 123, 1400, 10.1161/CIRCULATIONAHA.110.003210